Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009

Nephrology Dialysis Transplantation

Volumn 26, Issue 5, 2011, Pages 1583-1591

  Regidor, Deborah ^a   McClellan, William M ^b   Kewalramani, Reshma ^a   Sharma, Amit ^c   Bradbury, Brian D ^a  

^a AMGEN INC   (United States)

^b EMORY UNIVERSITY   (United States)

^c Boise Kidney and Hypertension Institute   (United States)

Author keywords

anaemia; chronic kidney disease; haemoglobin; non dialysis; trends

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; CROSS-SECTIONAL STUDY; DIALYSIS; DRUG USE; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; PRIORITY JOURNAL; RACE; REIMBURSEMENT; SEX DIFFERENCE; STAGING; UNITED STATES;

AGED; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROGNOSIS;

EID: 79951647537     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq573     Document Type: Article

References (40)

1. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047 (Pubitemid 350074801)
2. Erslev AJ, Besarab A. Erythropoietin in the pathogenesis and treat-ment of the anemia of chronic renal failure. Kidney Int 1997; 51: 622-630 (Pubitemid 27157944)
3. Nissenson AR, Nimer SD, Wolcott DL. Recombinant human erythro-poietin and renal anemia: molecular biology, clinical efficacy, and nervous system effects. Ann Intern Med 1991; 114: 402-16
4. Holland DC, Lam M. Predictors of hospitalization and death among pre-dialysis patients: a retrospective cohort study. Nephrol Dial Transplant 2000; 15: 650-658 (Pubitemid 30242983)
5. Jurkovitz CT, Abramson JL, Vaccarino LV et al. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atheroscler-osis risk in communities (ARIC) study. JAm Soc Nephrol 2003; 14: 2919-2925 (Pubitemid 37305654)
6. McClellan WM, Flanders WD, Langston RD et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. JAm Soc Nephrol 2002; 13: 1928-1936 (Pubitemid 34700619)
7. Al-Ahmad A, Rand WM, Manjunath G et al. Reduced kidney func-tion and anemia as risk factors for mortality in patients with left ven-tricular dysfunction. JAm Coll Cardiol 2001; 38: 955-962 (Pubitemid 32912694)
8. Alexander M, Bradbury BD, Kewalramani R et al. Chronic kidney disease and US healthcare resource utilization in a nationally repre-sentative sample. Am JNephrol 2009; 29: 473-482
9. Eschbach JW, Abdulhadi MH, Browne JK et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Re-sults of a phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992-1000 (Pubitemid 20034923)
10. Cody J, Daly C, Campbell M et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev 2005: CD003266
11. (R) (Epoetin Alfa) Prescribing Information. Thousand Oaks, CA: Amgen, 2007
12. Aranesp (Darbepoetin Alfa) Prescribing Information. Thousand Oaks, CA: Amgen, 2007
13. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoe-tin alfain chronickidney disease. NEngl J Med 2006; 355: 2085-2098 (Pubitemid 44749317)
14. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084 (Pubitemid 44749316)
15. Pfeffer MA, Burdmann EA, Chen C-Y et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
16. Besarab A, Bolton WK, Browne JK et al. The effects ofnormal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590 (Pubitemid 28385655)
17. Bohlius J, Langensiepen S, Schwarzer G et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. JNatl Cancer Inst 2005; 97: 489-498 (Pubitemid 40590430)
18. Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythro-poietins and cancer patients: updated meta-analysis of 57 studies in-cluding 9353 patients. J Natl Cancer Inst 2006; 98: 708-714 (Pubitemid 43821788)
19. Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembol-ism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299: 914-924 (Pubitemid 351397066)
20. Bennett CL, Henke M, Lai SY. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia-reply. JAMA 2008; 300: 2855-2857
21. Bohlius J, Schmidlin K, Brillant C et al. Recombinant human erythro-poiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 374: 1532-1542
22. Bohlius J, Schmidlin K, Brillant C et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with can-cer: a meta-analysis of randomised trials (erratum). Lancet 2009; 374: 28
23. Levey AS, Greene T, Kusek JW et al. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. JAm Soc Nephrol 2000; 11: A0828
24. Manjunath G, Sarnak MJ, Levey AS. Prediction equations to estimate glomerular filtration rate: an update. Curr Opin Nephrol Hypertens 2001; 10: 785-792 (Pubitemid 33043673)
25. Phrommintikul A, Haas SJ, Elsik M et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369: 381-388 (Pubitemid 46188479)
26. Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Prac-tice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update on Hemoglobin Target. Am J Kidney Dis 2007; 50: 479-512
27. Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, pla-cebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007; 25: 1027-1032 (Pubitemid 46596751)
28. Smith RE Jr, Aapro MS, Ludwig H et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, ran-domized, double-blind, placebo-controlled study. J Clin Oncol 2008; 26: 1022-1024
29. Rizzo JD, Somerfield MR, Hagerty KL et al. American Society of Clinical Oncology American Society of Hematology. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008; 26: 132-149
30. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology™. Cancer-and chemotherapy-induced anemia. V2.2009
31. Fishbane S, Nissenson AR. The new FDA label for erythropoietin treatment: how does it affect hemoglobin target? Kidney Int 2007; 27: 806-813 (Pubitemid 47462071)
32. Neumann ME. Managing anemia: what do we do now? Nephrol News Issues 2007; 21: 53-54
33. Singh AK. The FDA black box for EPO: what should nephrologists do? Nephrol News Issues 2007; 21: 55-56
34. Berns JS, Fishbane S, Elzein H et al. The effect of a change in epoe-tin alfa reimbursement policy on anemia outcomes in hemodialysis patients. Hemodial Int 2005; 9: 255-263 (Pubitemid 41131073)
35. Collins AJ, Ma JZ, Xia A et al. Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 1998; 32: S133-S141
36. Collins AJ, Roberts TL, St Peter WL et al. United States Renal Data System assessment of the impact of the National Kidney Foundation-Dialysis Outcomes Quality Initiative guidelines. Am J Kidney Dis 2002; 39: 784-795 (Pubitemid 34263353)
37. U.S. Renal Data System. USRDS 2008 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: Na-tional Institutes of Health, National Institute of Diabetes and Digest-ive and Kidney Diseases, 2008
38. Coyne DW, Kapoian T, Suki W et al. Ferric gluconate is highly effi-cacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study JAm Soc Nephrol 2007; 18: 975-984 (Pubitemid 46434515)
39. Ebben JP, Gilbertson DT, Foley RN et al. Hemoglobin level variabil-ity: associations with comorbidity, intercurrent events, and hospitali-zations. Clin J Am Soc Nephrol 2006; 1: 1205-1210
40. Solid CA, Foley RN, Gilbertson DT et al. Perihospitalization hemoglobin-epoetin associations in U.S. hemodialysis patients, 1998 to 2003. Hemodial Int 2007; 11: 442-447 (Pubitemid 47534870)